These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The relationship between the structure of dermatan sulfate derivatives and their antithrombotic activities. Du HY; Ji SL; Song HF; Ye QN; Cao JC Thromb Res; 2007; 119(3):377-84. PubMed ID: 17097136 [TBL] [Abstract][Full Text] [Related]
7. Dermatan sulphate induces plasminogen activator release in the perfused rat hindquarters. Abbadini M; Zhu GJ; Maggi A; Pangrazzi J; Donati MB; Mussoni L Blood; 1987 Dec; 70(6):1858-60. PubMed ID: 3676516 [TBL] [Abstract][Full Text] [Related]
8. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding. Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710 [TBL] [Abstract][Full Text] [Related]
9. Activation of heparin cofactor II by heparin and dermatan sulfate. Tollefsen DM Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic profile of sulfamino-galactosaminoglycans. Pescador R; Porta R; Mantovani M; Prino G; Casu B; Naggi A; Torri G; Walenga JM; Hoppensteadt DA; Fareed J Semin Thromb Hemost; 1991; 17 Suppl 1():74-9. PubMed ID: 1906197 [No Abstract] [Full Text] [Related]
11. [Effect of dermatan sulphate on plasminogen activator activity in perfused rat hindlegs]. Zhu GJ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Dec; 10(6):435-8. PubMed ID: 2978401 [No Abstract] [Full Text] [Related]
12. Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Fabiana Alberto M; Giaquinta Romero D; Lazzari M; Calabrese GC Thromb Res; 2008; 122(1):109-16. PubMed ID: 17936880 [TBL] [Abstract][Full Text] [Related]
13. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding. Buchanan MR; Brister SJ Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889 [TBL] [Abstract][Full Text] [Related]
14. Overview of hemostasis and thrombosis; current status of antithrombotic therapies. Horne M Thromb Res; 2005; 117(1-2):15-7; discussion 39-42. PubMed ID: 16055174 [No Abstract] [Full Text] [Related]
15. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Fonseca RJ; Mourão PA Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379 [TBL] [Abstract][Full Text] [Related]
16. Antithrombotic effects of the association standard heparin-dermatan sulfate. Caranobe C; Gabaig AM; Sié P; Boneu B Thromb Haemost; 1991 Jan; 65(1):107. PubMed ID: 2024232 [No Abstract] [Full Text] [Related]
17. Mechanical properties of reconstituted collagen fibrils. Influence of a glycosaminoglycan: dermatan sulfate. Danielsen CC Connect Tissue Res; 1982; 9(4):219-25. PubMed ID: 6215205 [TBL] [Abstract][Full Text] [Related]
18. Characterization of a novel dermatan sulfate with high antithrombin activity from ray skin (Raja radula). Ben Mansour M; Dhahri M; Bertholon I; Ollivier V; Bataille I; Ajzenberg N; Hassine M; Jandrot-Perrus M; Chaubet F; Maaroufi RM Thromb Res; 2009 Apr; 123(6):887-94. PubMed ID: 19019412 [TBL] [Abstract][Full Text] [Related]
19. [Mechanism of action of antithrombotic substances. General information about antagonistic and potentiating drugs]. Cornu P Rev Prat; 1973 Dec; 23(60):5365-8 passim. PubMed ID: 4794529 [No Abstract] [Full Text] [Related]
20. Dermatan sulfate isomers in human articular cartilage characterized by high-performance liquid chromatography. Murata K; Yokoyama Y Biochem Int; 1987 Jul; 15(1):87-94. PubMed ID: 3453690 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]